Sage Therapeutics (NASDAQ:SAGE) Price Target Cut to $25.00 by Analysts at HC Wainwright
The Cerbat Gem -

Sage Therapeutics (NASDAQ:SAGE – Get Free Report) had its price objective reduced by stock analysts at HC Wainwright from $28.00 to $25.00 in a research report issued to clients and investors on Friday, Benzinga reports. The firm presently has a “neutral” rating on the biopharmaceutical company’s stock. HC Wainwright’s target price indicates a potential upside […]

In related news